Skip to main content

Table 3 Effect of omega-3 on cardiometabolic indices in diabetic patients with NAFLD

From: Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial

Indices Omega-3 (n = 30) Placebo (n = 30) P P††
AIP     0.13
 Baseline 0.49 ± 0.22 0.44 ± 0.19 0.36
 Week 12 0.38 ± 0.28 0.41 ± 0.27 0.67
P 0.007 0.33  
 Mean change −0.11 ± 0.20 −0.03 ± 0.16 0.10
Castelli risk index I     0.46
 Baseline 3.63 ± 0.9 3.41 ± 0.7 0.31
 Week 12 3.38 ± 0.9 3.34 ± 0.7 0.88
P 0.05 0.62  
 Mean change −0.25 ± 0.6 −0.07 ± 0.7 0.29
Castelli risk index II     0.70
 Baseline 2.11 ± 0.6 1.97 ± 0.5 0.55
 Week 12 1.87 ± 0.6 1.83 ± 0.5 0.81
P 0.01 0.15  
 Mean change −0.24 ± 0.5 −0.14 ± 0.5 0.47
AC     0.40
 Baseline 2.63 ± 0.9 2.41 ± 0.7 0.31
 Week 12 2.38 ± 0.9 2.34 ± 0.7 0.88
P 0.05 0.62  
 Mean change −0.25 ± 0.6 −0.07 ± 0.7 0.29
  1. P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD)
  2. P: resulted from comparisons within groups by paired t-test
  3. P: resulted from comparisons between two groups by independent t-test
  4. P††: resulted from comparing the mean change from baseline between groups using univariate ANCOVA after adjusting for energy intake and weight change
  5. NAFLD Non-alcoholic fatty liver disease, AIP Atherogenic index of plasma, AC Atherogenic coefficient